Korean firm PharmAbcine, a clinical-stage biotechnology company, announced that the company entered into a license agreement with US based Wincal Biopharm (Wincal), a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the commercial value of PharmAbcine's existing and future assets through R&D efforts. 

Under this agreement, Wincal will use PharmAbcine's assets to develop new platforms that can enhance biological activities of traditional antibody therapeutic to target broader disease areas.

Wincal's efforts will be spearheaded by Dr. Tae-Weon Lee, Chief Scientific Officer and a founding member of Wincal. Dr. Lee has over 20 years of pharmaceutical industry experience in overseeing drug discovery efforts and supporting scientific collaborative efforts with academics and pharmaceutical companies.

Before joining Wincal, he was a director and a principal investigator leading the diabetes and heart failure drug discovery program at Amgen.